Updated:
Life Sciences Research Partners
Life Sciences Research Partners invests in early-stage therapeutics and diagnostics from offices in Danbury and Leuven, with a transatlantic focus.
Life Sciences Research Partners
Life Sciences Research Partners is an investment firm focused on the life sciences sector, with a particular emphasis on early-stage therapeutics and diagnostics. The firm maintains offices in Danbury, Connecticut, and Leuven, Belgium, suggesting a strategy that bridges US and European opportunities. Its founding team and wealth origin are not publicly documented, which limits visibility into its governance structure. The firm targets investments in companies developing novel drug discovery platforms, precision medicine tools, and digital health technologies. It typically leads or co-leads seed and Series A rounds, taking board seats and providing operational support to portfolio companies. Publicly named investments include a role in the 2018 $55M Series C for Harpoon Therapeutics (per SEC filing, 2018). The firm also backed Seer, a proteomics company that went public in 2020 (per S-1 filing, 2020). Geographically, it balances US and European deal flow, with a concentration in the Boston-Cambridge corridor and the Belgian biotech cluster anchored by KU Leuven. The firm's total assets under management are not publicly disclosed. Its professional headcount is unknown, and it does not operate any publicly identifiable adjacent vehicles such as a companion venture fund or philanthropic foundation. No recent operational event — such as a new fund close or leadership change — is available from public sources for the past 24 months. LSRP's structural differentiator is its transatlantic platform, rare among early-stage life sciences venture investors. The ability to originate in both the US and European innovation hubs — and to support portfolio companies with regulatory and clinical expertise across both markets — is a distinguishing operational feature. The firm's governance and succession plans remain opaque.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Danbury
Corporate office
Danbury, CT, United States
Additional offices
Leuven, Belgium
Sector focus
Frequently asked questions
What investment stages does Life Sciences Research Partners typically target?
The firm focuses on early-stage companies, typically leading or co-leading seed and Series A rounds. It seeks to take board seats and provide hands-on operational support. This stage focus aligns with its strategy of identifying novel science before later-stage validation (per corporate filings and firm communications).
Does Life Sciences Research Partners invest in non-US companies?
Yes. The firm's office in Leuven, Belgium, indicates a clear European commitment. Portfolio companies include firms based in both the United States and Europe, particularly in the Belgian biotech cluster around KU Leuven. This transatlantic reach allows the firm to source deals across two major innovation hubs.
Is Life Sciences Research Partners structured as a venture capital firm or a family office?
The firm operates as an investment manager focused on life sciences, but its ownership and wealth base are not publicly documented. It does not self-identify as a family office, and no public records confirm family-office status. The structure appears closest to an independent venture capital firm (per public record).
Who runs investment decisions at Life Sciences Research Partners?
The principals and investment committee members are not disclosed in easily accessible public materials. The lack of named partners on the firm's limited web presence makes governance opaque. This is a known limitation for allocators seeking transparency (per Altss research).
What sectors does Life Sciences Research Partners explicitly avoid?
The firm does not publicly declare any exclusion list. Based on its sector focus, it likely avoids later-stage buyouts, infrastructure, and non-life-sciences technology. Without explicit statements, this remains inferential (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: